Methylphenidate Viatris

Methylphenidate, the active ingredient in Methylphenidate Viatris, is a central nervous system stimulant presented as an oral dosage form for oral use. It is prescribed for the management of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across global markets with consistent quality and regulatory compliance.

Methylphenidate is a central nervous system stimulant used in the treatment of neurodevelopmental and sleep‑wake disorders.

- Attention Deficit Hyperactivity Disorder (ADHD): improves focus, reduces hyperactivity and impulsivity. - Adult ADHD: provides similar benefits in concentration and behavioral control for adult patients. - Narcolepsy: decreases excessive daytime sleepiness and helps maintain wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Nervousness: feelings of anxiety or restlessness. - Elevated blood pressure: modest increase in systolic/diastolic values.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, arrhythmia, or sudden cardiac death. - Psychosis or severe agitation: hallucinations, delusional thinking. - Priapism: prolonged, painful erection. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Tics or motor disturbances: involuntary movements. - Mania or bipolar exacerbation: heightened mood swings.

Before initiating therapy, clinicians should consider several safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart history. - Psychiatric screening: review history of psychosis, bipolar disorder, or severe anxiety. - Growth monitoring: track height and weight in pediatric patients. - MAO inhibitor avoidance: ensure a 14‑day washout period before starting. - Seizure risk: use cautiously in patients with a seizure disorder. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Antihypertensive agents: may reduce blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Tricyclic antidepressants: increased risk of cardiovascular side effects. - Anticonvulsants (e.g., carbamazepine): may lower methylphenidate plasma levels. - Proton‑pump inhibitors: potential modest increase in methylphenidate exposure.